Search 

Clayton Biotechnologies commercializes technologies that are developed and owned by the Clayton Foundation for Research and its supporting entities through research programs at leading research hospitals and institutions in the US and Switzerland.

We have several projects in various stages of development from discovery to advanced pre-clinical that are available for licensing, collaboration, and the creation of new start-up ventures.

Clayton Biotechnologies has a significant portfolio of technologies to offer for licensing and collaboration. 

Some of our featured technologies:

- Urocortins and analogues for Diabetes

- Fc engineering of aglycosylated antibodies

- Granzyme B - a potent payload for antibody drug conjugates (ADC)

- Alk4-Fc, a Cripto antagonist for Cancer

- TEAD gene and peptide therapies for ocular neovascular disease

- Stem cell therapy program for Parkinson's Disease

- Vaccines and Diagnostics for Ehrlichioses

- Biomarker for personalized breast cancer therapy

- YESS - engineering of proteases

- OCT Image Guided Smart Laser Knife Diagnosis and Therapy in Small Spaces

To date, 9 products based on Clayton Foundation discoveries have been have been successfully commercialized through the creation of start-up companies and out-licensing

We have developed the CloSys Hemostatic Device (HD)  - a highly differentiated technology for vascular closure after an interventional cardiology or peripheral procedure.  CloSys HD is unique in that it facilitates rapid closure but leaves NO foreign material behind in the patient.  It does this using a patented technology that eliminates heparin (anti-coagulant) from a small amount of the patient's blood and re-infuses this back to the puncture site and around the entire artery.  The de-heparinized blood rapidly and safely forms a clot to seal the artery naturally.  There are several other unique attributes of this product.  First  - it is the only product that will also seal "backsticks" or inadvertant punctures that go through the other side of the artery.  Backsticks are a leading cause of retroperitoneal hemorrhage.  Second - it preserves immediate re-access at the same site in the advent of an emergency.  

There is also an important economic value proposition offered by CloSys HD.  It will have a very low cost of goods so it could be sold for a price that will allow high margins to the manufacturer and cost savings to the hospital.  

We are approximately 25% of the way through a US pivotal trial and to date all performance and safety endpoints have been met.  There is a highly experienced management team and exceptional Board of Directors now associated with the company.    

The Colorado Institute for Drug, Device and Diagnostic Development (CID4) is a 501(c)3 not-for-profit entity committed to economic development through the creation and funding of Colorado Life Science companies. Our goal is to efficiently transform emerging life science innovations into commercial successes. First, we use a rigorous review process and advisory panel to select promising post-proof-of-concept technologies from Colorado’s outstanding research institutions and start-up companies. Second, we fund and actively manage product development while taking an equity position in existing companies and in new companies that we found with the inventors. Third, we facilitate additional seed and/or grant funding to further develop our portfolio companies technologies. By augmenting the value of these innovations, we position our portfolio companies to attract series A financing from venture capitalists and/or partnering opportunities with established pharmaceutical and biotechnology companies. We have funded 9 early stage companies since June 2010 and these companies have raised more than $30 million in additional private capital and grant funding.